Lennham Consumer Products Announces Publication of Manuscripts Describing Clinical and Non-Clinical PK and Safety of d9-Caffeine
Retrieved on:
星期五, 七月 29, 2022
Supply Chain Management, Retail, Specialty, Food, Beverage, Traffic barrier, Psilocybin, Coffee, Insomnia, Half-life, Tmax, Code, GRAS, Testosterone, Cmax, Deuterium, Regulatory Toxicology and Pharmacology, CYP1A2, Energy, Safety, Metabolism, Interindividual differences in perception, CYP450, Food and Chemical Toxicology, PK, Element, FDA, Pharmacokinetics, Hydrogen, Final good, The New England Journal of Medicine, Mammal, Manuscript, Pharmaceutical industry, Lithium, Food, Caffeine, Pharmacology, Health
Lennham Consumer Products, a start-up focused on the creative use of deuterium chemistry to improve well-known products, today announced the publication of two manuscripts describing the clinical and non-clinical pharmacokinetics (PK) and safety of d9-caffeine.
Key Points:
- Lennham Consumer Products, a start-up focused on the creative use of deuterium chemistry to improve well-known products, today announced the publication of two manuscripts describing the clinical and non-clinical pharmacokinetics (PK) and safety of d9-caffeine.
- Results indicate that both d9-caffeine and normal caffeine were well tolerated, and no adverse events for insomnia were reported.
- The second manuscript, published in Food and Chemical Toxicology, reports on studies examining the non-clinical safety, pharmacology, and pharmacokinetics of d9-caffeine.
- In 2019, Lennham set out to improve caffeine by creating an enhanced version that provides the same benefits but lasts longer.